Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Radiology Business
Hybrid AI Approach Cuts Mammography Workload by 38%
A Dutch research team demonstrated that a 'hybrid' AI strategy can reduce radiologist workload in mammography screening by nearly 40% without affecting performance.
•Cardiovascular Business
Former US Surgeon General Jerome Adams Joins Eko as Medical Advisor
Former US Surgeon General Jerome Adams has joined Eko Health as a distinguished medical advisor to support AI-powered cardiac and pulmonary detection technologies.
•AuntMinnie
Hybrid AI-Human Mammography Reading Cuts Workload Without Compromising Cancer Detection
A hybrid AI and radiologist reading strategy for screening mammography reduced radiologist workload by 38% without affecting recall or cancer detection rates.